What is Leerink Partnrs’ Estimate for UTHR FY2024 Earnings?

United Therapeutics Co. (NASDAQ:UTHR) – Stock analysts at Leerink Partnrs reduced their FY2024 EPS estimates for shares of United Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now expects that the biotechnology company will earn $25.09 per share for the year, down from their previous forecast of $25.94. The consensus estimate for United Therapeutics’ current full-year earnings is $25.21 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q1 2025 earnings at $6.95 EPS, Q2 2025 earnings at $7.31 EPS, Q3 2025 earnings at $7.81 EPS, FY2025 earnings at $29.77 EPS, FY2026 earnings at $31.02 EPS, FY2027 earnings at $30.53 EPS and FY2028 earnings at $32.83 EPS.

A number of other research firms also recently issued reports on UTHR. TD Cowen upped their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. LADENBURG THALM/SH SH upped their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Oppenheimer upped their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. The Goldman Sachs Group upped their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. Finally, Argus upped their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $382.08.

United Therapeutics Trading Up 4.9 %

United Therapeutics stock opened at $370.74 on Wednesday. United Therapeutics has a 1 year low of $211.61 and a 1 year high of $417.82. The company has a market cap of $16.55 billion, a PE ratio of 16.28, a PEG ratio of 0.92 and a beta of 0.57. The company’s 50-day moving average is $361.99 and its two-hundred day moving average is $358.32.

Insider Buying and Selling

In other news, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $896,950.62. This trade represents a 79.51 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Nilda Mesa sold 255 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now directly owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 121,864 shares of company stock valued at $44,516,965. 11.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds have recently made changes to their positions in UTHR. Newbridge Financial Services Group Inc. bought a new position in shares of United Therapeutics during the 4th quarter worth approximately $25,000. Brooklyn Investment Group bought a new position in shares of United Therapeutics in the third quarter valued at $33,000. Millstone Evans Group LLC bought a new position in shares of United Therapeutics in the fourth quarter valued at $67,000. Capital Performance Advisors LLP bought a new position in shares of United Therapeutics in the third quarter valued at $82,000. Finally, MassMutual Private Wealth & Trust FSB grew its stake in shares of United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 58 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.